Management of bladder cancer provides a single, comprehensive reference source that incorporates all the latest information regarding bladder cancer. The text covers epidemiology and natural history of bladder cancer as well as latest findings regarding the genetics and molecular biology of the disease. Diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer is discussed. The text incorporates chapters summarizing new findings regarding markers for the diagnosis of bladder cancer and new diagnostic techniques to enhance traditional methods such as cystoscopy.…mehr
Management of bladder cancer provides a single, comprehensive reference source that incorporates all the latest information regarding bladder cancer. The text covers epidemiology and natural history of bladder cancer as well as latest findings regarding the genetics and molecular biology of the disease. Diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer is discussed. The text incorporates chapters summarizing new findings regarding markers for the diagnosis of bladder cancer and new diagnostic techniques to enhance traditional methods such as cystoscopy. Risk stratified treatment of non muscle invasive bladder cancer including various approaches to intravesical therapy are reviewed. Current guideline based approaches to management and new data regarding diagnosis and prognostication of muscle invasive bladder cancer is analyzed and summarized. The application of chemotherapy for muscle invasive and advanced disease is discussed and the evidence based application of multimodality therapy highlighted. Finally, gaps in current knowledge and areas for future research are highlighted. Ongoing important clinical trials which could imminently yield significant new knowledge is discussed.
Authored by experts in their respective fields, Management of Bladder Cancer will serve as a easy and complete reference source for clinicians, researchers, individuals in training, allied health professionals and medical students in the fields of Urology, Medical Oncology, Radiation Oncology, Basic and Translational Science and Epidemiology.
Artikelnr. des Verlages: 86153721, 978-1-4939-1880-5
2015
Seitenzahl: 500
Erscheinungstermin: 17. November 2014
Englisch
Abmessung: 260mm x 183mm x 33mm
Gewicht: 1200g
ISBN-13: 9781493918805
ISBN-10: 149391880X
Artikelnr.: 41203968
Herstellerkennzeichnung
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Badrinath R. Konety, MD, MBA, FACS Professor and Chair, Dept. of Urology Dougherty Family Chair in Urologic Oncology Associate Director for Clinical Affairs, Masonic Cancer Center University of Minnesota MMC 394, 420 Delaware St Minneapolis MN 55455, USA Sam S. Chang, MD, FACS Professor of Urologic Surgery Patricia and Rodes Hart Chair of Urologic Surgery Department of Urologic Surgery Vanderbilt University Medical Center MCN A 1302, VUMC Nashville, TN 37232, USA
Inhaltsangabe
Epidemiology and natural history.- Screening for Bladder Cancer.- Pathology and Staging: Histopathology and Cytopathology.- Pathology and Staging: Genetics and Molecular Biology.- Imaging in Localized and Advanced Bladder Cancer.- New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder.- Socioeconomic issues and improved quality of care.- Quality of life measures.- Prognostication and risk assessment.- Clinical trials and emerging therapeutic strategies in bladder cancer.- Improved diagnostic techniques.- Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging.- Localized surgical therapy and surveillance.- Clinical Scenario: Initial high grade Ta tumor.- Clinical Scenario: Recurrent Ta tumor.- Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor.- Clinical Scenario: Low grade T1 tumor.- Intravesical therapy.- Clinical Scenario: Initial CIS.- Management of BCG Recurrent Bladder Cancer.- Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG.- Maurizio Brausi.- Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation.- Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines.- Open Radical Cystectomy.- Robotic cystectomy.- Clinical Scenario: T2 bladder tumor.- Urinary Diversion: Open and robotic techniques.- Chemoradiotherapy.- Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation.- Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application.- Clinical Scenario: Large volume, non metastatic T2 bladder tumor.- The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.- Clinical Scenario: Unexpected positive nodes at radical cystectomy.- Surveillance andmonitoring.- Clinical Scenario: The Role of Perioperative Chemotherapy.- Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy.- Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAU.
Epidemiology and natural history.- Screening for Bladder Cancer.- Pathology and Staging: Histopathology and Cytopathology.- Pathology and Staging: Genetics and Molecular Biology.- Imaging in Localized and Advanced Bladder Cancer.- New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder.- Socioeconomic issues and improved quality of care.- Quality of life measures.- Prognostication and risk assessment.- Clinical trials and emerging therapeutic strategies in bladder cancer.- Improved diagnostic techniques.- Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging.- Localized surgical therapy and surveillance.- Clinical Scenario: Initial high grade Ta tumor.- Clinical Scenario: Recurrent Ta tumor.- Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor.- Clinical Scenario: Low grade T1 tumor.- Intravesical therapy.- Clinical Scenario: Initial CIS.- Management of BCG Recurrent Bladder Cancer.- Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG.- Maurizio Brausi.- Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation.- Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines.- Open Radical Cystectomy.- Robotic cystectomy.- Clinical Scenario: T2 bladder tumor.- Urinary Diversion: Open and robotic techniques.- Chemoradiotherapy.- Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation.- Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application.- Clinical Scenario: Large volume, non metastatic T2 bladder tumor.- The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.- Clinical Scenario: Unexpected positive nodes at radical cystectomy.- Surveillance andmonitoring.- Clinical Scenario: The Role of Perioperative Chemotherapy.- Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy.- Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAU.
Rezensionen
From the book reviews:
"The target audience is researchers, clinicians, trainees, allied health professionals, and medical students. Given the emphasis and specificity of the chapters on early stage bladder cancer, this book seems most geared to urologists and urology trainees. ... This is a very easy to use, clearly and expertly written, case- and clinical scenario-based reference that will be helpful to all who treat and study bladder cancer." (Jean Hoffman-Censits, Doody's Book Reviews, March, 2015)
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826